Vitamin D in chronic liver disease

Liver International

Volumn 33, Issue 3, 2013, Pages 338-352

  Stokes, Caroline S ^a   Volmer, Dietrich A ^b   Grünhage, Frank ^a   Lammert, Frank ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

25 hydroxyvitamin D; Bioavailability; Cholecalciferol; Epimers; Hepatic disease; Hepatic osteodystrophy; Vitamin D metabolites

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; PEGINTERFERON; RIBAVIRIN; VITAMIN D;

ACUTE GRAFT REJECTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOLIC FATTY LIVER; BIOLOGICAL FUNCTIONS; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; DISEASES; FOOD COMPOSITION; FOOD INTAKE; GENETIC ASSOCIATION; HEPATITIS C; HUMAN; LIQUID CHROMATOGRAPHY; LIVER FIBROSIS; MASS SPECTROMETRY; METABOLITE; NONHUMAN; OSTEODYSTROPHY; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

AGE FACTORS; CHRONIC DISEASE; FEMALE; HUMANS; LIVER DISEASES; MALE; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR STRUCTURE; PREVALENCE; SEX FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84873731007     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12106     Document Type: Review

References (87)

1. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-56.
2. Leslie W. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-66.
3. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624-8.
4. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50(Suppl 1): i1-9.
5. EASL. EASL Clinical practice guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
6. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009; 156: 7-27.
7. Plum LA, Deluca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010; 9: 941-55.
8. Plum L, Deluca H. The functional metabolism and molecular biology of vitamin D action. Clin Rev Bone Miner Metab 2009; 7: 20-41.
9. Ho A-S, Cheng C-C, Lee S-C, et al. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010; 17: 58.
10. Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: Roles in response to injury. Clin Chem 2006; 52: 1247-53.
11. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-12.
12. Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol 2011; 35: 295-302.
13. Lin R, White JH. The pleiotropic actions of vitamin D. BioEssays 2004; 26: 21-8.
14. White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord 2012; 13: 21-9.
15. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009; 94: 26-34.
16. Chesney RW. Vitamin D and the magic mountain: The anti-infectious role of the vitamin. J Pediatr 2010; 156: 698-703.
17. Vogeser M, Kyriatsoulis A, Huber E, Kobold U. Candidate reference method for the quantification of circulating 25-hydroxyvitamin D3 by liquid chromatography-tandem mass spectrometry. Clin Chem 2004; 50: 1415-7.
18. Ding S, Schoenmakers I, Jones K, et al. Quantitative determination of vitamin D metabolites in plasma using UHPLC-MS/MS. Anal Bioanal Chem 2010; 398: 779-89.
19. Nakagawa K, Sowa Y, Kurobe M, et al. Differential activities of 1alpha, 25-dihydroxy-16-ene-vitamin D(3) analogs and their 3-epimers on human promyelocytic leukemia (HL-60) cell differentiation and apoptosis. Steroids 2001; 66: 327-37.
20. Kamao M, Tatematsu S, Hatakeyama S, et al. C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J Biol Chem 2004; 279: 15897-907.
21. Carter GD. Accuracy of 25-hydroxyvitamin D assays: Confronting the issues. Curr Drug Targets 2011; 12: 19-28.
22. Couchman L, Benton CM, Moniz CF. Variability in the analysis of 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry: The devil is in the detail. Clin Chim Acta 2012; 413: 1239-43.
23. Singh RJ. C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrin Metab 2006; 91: 3055-61.
24. Shah I, James R, Barker J, Petroczi A, Naughton DP. Misleading measures in Vitamin D analysis: A novel LC-MS/MS assay to account for epimers and isobars. Nutr J 2011; 10: 46.
25. Lensmeyer G, Poquette M, Wiebe D, Binkley N. The C-3 epimer of 25-hydroxyvitamin D(3) is present in adult serum. J Clin Endocrinol Metab 2012; 97: 163-8.
26. Mawer EB, Backhouse J, Holman CA, Lumb GA, Stanbury SW. The distribution and storage of vitamin D and its metabolites in human tissues. Clin Sci 1972; 43: 413-31.
27. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-3.
28. St-Arnaud R, Glorieux FH. 24, 25-Dihydroxyvitamin D-active metabolite or inactive catabolite? Endocrinology 1998; 139: 3371-4.
29. Prentice A, Goldberg GR, Schoenmakers I. Vitamin D across the lifecycle: physiology and biomarkers. Am J Clin Nutr 2008; 88: 500S-06S.
30. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clinical Endocrin Metab 2011; 96: 1911-30.
31. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128: 1414-24.
32. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92: 2017-29.
33. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 2005; 294: 2336-41.
34. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7: 439-43.
35. Osteoporosis WSGotPaMo. Prevention and Management of Osteoporosis: Report of a WHO Scientific Group. Geneva: WHO, 2003.
36. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2011.
37. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5: 513-20.
38. Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996; 11: 417-21.
39. Monegal A, Navasa M, Guanabens N, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997; 60: 148-54.
40. Cholongitas E, Theocharidou E, Goulis J, et al. Review article: The extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther 2012; 35: 634-46.
41. Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, et al. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int 2010; 4: 634-40.
42. Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol 2010; 34: 618-20.
43. Putz-Bankuti C, Pilz S, Stojakovic T, et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int 2012; 32: 845-51.
44. Crawford BAL, Kam C, Donaghy AJ, Mccaughan GW. The heterogeneity of bone disease in cirrhosis: A multi-variate analysis. Osteoporos Int 2003; 14: 987-94.
45. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-24.
46. Barchetta I, Angelico F, Ben M, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine 2011; 9: 85.
47. Trautwein C, Possienke M, Schlitt HJ, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000; 95: 2343-51.
48. Bitetto D, Fabris C, Falleti E, et al. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 2010; 30: 417-44.
49. Corey KE, Zheng H, Mendez-Navarro J, et al. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS ONE 2012; 7: e27144.
50. Bikle DD, Halloran BP, Gee E, Ryzen E, Haddad JG. Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. J Clin Invest 1986; 78: 748-52.
51. Safadi FF, Thornton P, Magiera H, et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999; 103: 239-51.
52. Zella LA, Shevde NK, Hollis BW, Cooke NE, Pike JW. Vitamin D-binding protein influences total circulating levels of 1, 25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 2008; 149: 3656-67.
53. Mawer EB, Klass HJ, Warnes TW, Berry JL. Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease. Clin Sci(Lond) 1985; 69: 561-70.
54. Compston JE. Hepatic osteodystrophy: Vitamin D metabolism in patients with liver disease. Gut 1986; 27: 1073-90.
55. Caniggia A, Lore F, di Cairano G, Nuti R. Main endocrine modulators of vitamin D hydroxylases in human pathophysiology. J Steroid Biochem 1987; 27: 815-24.
56. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 2010; 376: 180-8.
57. Grünhage F, Hochrath K, Krawczyk M, et al. Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology 2012; 56: 1883-91.
58. Baur K, Mertens JC, Schmitt J, et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int 2012; 32: 635-43.
59. Vogel A. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35: 126-31.
60. Tanaka A, Nezu S, Uegaki S, et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol 2009; 50: 1202-9.
61. Kempinska-Podhorecka A, Wunsch E, Jarowicz T, et al. Vitamin D receptor polymorphisms predispose to primary biliary cirrhosis and severity of the disease in polish population. Gastroenterol Res Pract 2012; 2012: 408723.
62. Falleti E. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol 2010; 16: 3016.
63. Petta S, Camma C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-67.
64. Bitetto D, Fattovich G, Fabris C, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118-26.
65. Nakano T, Cheng YF, Lai CY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2011; 55: 415-25.
66. Thompson KJ, Mckillop IH, Schrum LW. Targeting collagen expression in alcoholic liver disease. World J Gastro-enterol 2011; 17: 2473-81.
67. Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 2005; 9: 747-66.
68. Compston J. US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr Rheumatol Rep 2004; 6: 66-9.
69. Ruiz-Gaspa S, Martinez-Ferrer A, Guanabens N, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011; 54: 2104-13.
70. Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep 2011; 13: 40-48.
71. Guañabens N, Parés A. Management of osteoporosis in liver disease. Clin Res Hepatol Gastroenterol 2011; 35: 438-45.
72. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271-8.
73. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316-23.
74. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89: 47-50.
75. Shiomi S, Masaki K, Habu D, et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. J Gastroenterol 1999; 34: 241-5.
76. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
77. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: A link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-30.
78. Pourgholami MH, Akhter J, Lu Y, Morris DL. In vitro and in vivo inhibition of liver cancer cells by 1, 25-dihydroxyvitamin D3. Cancer Lett 2000; 151: 97-102.
79. Seubwai W, Wongkham C, Puapairoj A, Khuntikeo N, Wongkham S. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma. Cancer 2007; 109: 2497-505.
80. Malham M. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol 2011; 17: 922.
81. Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887-93.
82. Bitetto D, Fabris C, Fornasiere E, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24: 43-50.
83. Abu Mouch SFZ, Jarchovsky J, Assy N. Vitamin D supplement improves svr in chronic hepatitis C (genotype 1) naive patients treated with PEG interferon and ribavirin [Abstract]. J Hepatol 2010; 52: S23-41.
84. Von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11: 344-9.
85. Hopkins MH, Owen J, Ahearn T, et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res (Phila) 2011; 4: 1645-54.
86. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80(6 Suppl): 1678S-88S.
87. Fisher L, Byrnes E, Fisher AA. Prevalence of vitamin K and vitamin D deficiency in patients with hepatobiliary and pancreatic disorders. Nutr Res 2009; 29: 676-83.